Publisher’s Take note: MDPI stays neutral with regards to jurisdictional claims in printed maps and institutional affiliations. Additional procedure options which includes bDMARDs, tsDMARDs, biosimilars or mix therapy are offered when csDMARDs are ineffective or poorly tolerated. bDMARDs are a more recent option for the therapy of RA and supply https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/